Search Results
Apr 30, 2026, 07:30 ET Jersey Central Power & Light Company Announces Launch of Exchange Offer for Its 4.150% Senior Notes Due 2029, 4.400% Senior Notes Due 2031 and 5.150% Senior Notes Due 2036
declared effective on April 23, 2026.JCP&L serves approximately 1.2 million customers in the counties of Burlington, Essex, Hunterdon, Mercer, Middlesex, Monmouth, Morris, Ocean, Passaic, Somerset, Sussex, Union and Warren. Follow JCP&L on X @JCP_L, on Facebook at facebook.com/JCPandL or online
More news about: FirstEnergy Corp.
Apr 30, 2026, 07:04 ET Mercy Awarded Funding to Strengthen Care for Patients With Chronic High Blood Pressure
funding award will support Mercy in delivering clinically meaningful improvements in hypertension management," said PCORI Executive Director Dr. Nakela L. Cook. "This project exemplifies PCORI's commitment to making the results of patient-centered CER more accessible and usable in real-world settings, helping
More news about: Mercy
Apr 30, 2026, 06:45 ET Life Time Closes on $200 Million in Sale‑Leaseback Transactions
lives through its more than 190 athletic country clubs across the U.S. and Canada, the complimentary and comprehensive Life Time app featuring its L•AI•C™ AI powered health companion, and more than 30 iconic athletic events. Serving people ages 90 days to 90+ years, the Life Time ecosystem uniquely delivers
More news about: Life Time Group Holdings, Inc.
Apr 30, 2026, 06:30 ET Spin Master Reports Q1 2026 Financial Results and Reiterates 2026 Full Year Outlook
days.DIAL-IN: To join the conference call without operator assistance, you may register and enter your phone number at https:// emportal.ink/4b6l8iY to receive an instant automated call back. You can also dial direct to be entered to the call by an Operator: 1-416-945-7677 or 1-888-699-1199.About
More news about: Spin Master Corp.
Apr 30, 2026, 06:00 ET IDEAYA Biosciences to Initiate New Drug Application Submission from the Darovasertib OptimUM-02 Trial under the Oncology Center of Excellence Real-time Oncology Review (RTOR) Program
agreed to review its New Drug Application (NDA) for darovasertib in combination with crizotinib (darovasertib combination) for patients with first line (1L) HLA*A2-negative metastatic uveal melanoma (mUM) under the Oncology Center of Excellence (OCE) Real-Time Oncology Review (RTOR) program.
More news about: IDEAYA Biosciences, Inc.
Apr 30, 2026, 06:00 ET ValorC3 Data Centers Announces Closing of a Credit Facility With Apterra Infrastructure Capital To Fund the Continued Development of an Anchored Hyperscale Data Center Campus in Boise, Idaho
ity-with-apterra-infrastructure-capital-to-fund-the-continued-development-of-an-anchored-hyperscale-data-center-campus-in-boise-idaho-302758081.htmlSOURCE ValorC3 Data Centers
More news about: ValorC3 Data Centers
Apr 30, 2026, 06:00 ET Lanvin Group Continues Strategic Transformation in FY2025 as Momentum Improves in the Second Half
Lanvin Group Consolidated P&L2023A*
More news about: Lanvin Group
Apr 30, 2026, 05:01 ET Group 1 Automotive Reports First Quarter 2026 Financial Results
recent and future acquisitions and realize the expected benefits from consummated acquisitions, (k) foreign exchange controls and currency fluctuations, (l) the armed conflicts in Ukraine and the Middle East, (m) our ability to maintain sufficient liquidity to operate, and (n) a material failure in or breach
More news about: Group 1 Automotive, Inc.
Apr 30, 2026, 03:00 ET Fermi Inc. Appoints Rob L. Masson II as Interim Chief Financial Officer
Inc. (d/b/a Fermi America) (NASDAQ: FRMI) (LSE: FRMI), operating as Fermi America™ ("Fermi" or the "Company"), today announced the appointment of Rob L. Masson II as Interim Chief Financial Officer (CFO). Masson brings over two decades of experience in financial leadership and capital strategy, having
More news about: Fermi Inc.
Apr 30, 2026, 02:53 ET Hexagon releases new targets at its Capital Markets Day 2026
R&DHexagon is introducing EBITAC as its primary profitability measure. By immediately reflecting the full cost of R&D investments on the P&L, it will provide a tool to focus management firmly on the return on investment of R&D, go-to-market and capital investments and support performance
More news about: Hexagon
Apr 29, 2026, 23:13 ET D3 Bio Presents KRAS Pipeline Updates at AACR 2026; Elisrasib (D3S-001), a Next-Generation KRAS G12C Inhibitor, Shows Strong Phase 2 Efficacy Across Multiple Tumor Types
clinical outcomes include:2L+ KRAS G12Ci–naïve NSCLC: ORR of 58.8%, mPFS of 12.2 months2L+ colorectal cancer (CRC): ORR of 46.9%, mPFS of 9.5 months2L+ pancreatic ductal adenocarcinoma (PDAC): ORR of 65.0%, mPFS of 13.5
More news about: D3 Bio
Apr 29, 2026, 22:48 ET Taiwan Legislator Delivers Bitcoin Policy Institute Report on Bitcoin Reserve to Premier and Central Bank Governor
https://youtu.be/3L5Spqd4oN4?si=ygKUmHjyTtx3nox0&t=746Taiwan operates under a semi-presidential system in which the premier leads the executive branch and holds significant
More news about: Bitcoin Policy Institute
Apr 29, 2026, 21:16 ET LG Energy Solution Releases 2026 First-Quarter Financial Results
America, comprising three standalone facilities (Holland, Lansing, Windsor) and two joint venture facilities (Ultium Cells facility in Tennessee and L-H Battery Company in Ohio). Leveraging this robust production network, the company will secure over 50GWh of ESS battery production capacity in the region
More news about: LG Energy Solution
Apr 29, 2026, 18:30 ET LEPAS apresenta estratégia no Salão do Automóvel de Pequim e inicia um novo capítulo global
técnicas, a LEPAS escolheu seguir um caminho diferente. Durante o Salão de Pequim, que acontece na China entre 24 de abril e 3 de maio, os modelos LEPAS L6 BEV e L4 BEV farão sua estreia mundial. Desenvolvidos com base em três pilares centrais — "Leopard Aesthetics", design espacial refinado e dinâmica de condução
More news about: LEPAS
Apr 29, 2026, 17:15 ET Denecimig (Mim8) significantly reduced annualized bleeding rate in people with hemophilia A, regardless of inhibitor status, in phase 3 data published in NEJM
https://clinicaltrials.gov/study/NCT05878938.Lentz S, Chowedary P, Gil L, et al. FRONTIER1: a partially randomized phase 2 study assessing the safety, pharmacokinetics, and pharmacodynamics of Mim8, a factor VIIIa mimetic.
More news about: Novo Nordisk
Apr 29, 2026, 17:07 ET Denecimig (Mim8) significantly reduced annualized bleeding rate in people with hemophilia A, regardless of inhibitor status, in phase 3 data published in NEJM
https://clinicaltrials.gov/study/NCT05878938.Lentz S, Chowedary P, Gil L, et al. FRONTIER1: a partially randomized phase 2 study assessing the safety, pharmacokinetics, and pharmacodynamics of Mim8, a factor VIIIa mimetic.
More news about: Novo Nordisk
Apr 29, 2026, 16:55 ET Greenberg Traurig's House Band, The Meltones, Plays It Forward for The Headstrong Project, Again Wins Law Rocks LA
Stephen L. Rabinowitz and
More news about: Greenberg Traurig, LLP
Apr 29, 2026, 16:39 ET Wesley N. Slagle Elected to the RPC, Inc. Board of Directors
and Investor Relations(404) [email protected] Michael L. SchmitChief Financial Officer(404) [email protected]
More news about: RPC, Inc.
Apr 29, 2026, 16:37 ET /C O R R E C T I O N -- Barker Wellness/
and recoveryFormulated with a blend of Chaga, Lion's Mane, Cordyceps, and Reishi mushrooms plus adaptogens Lemon Balm, Passion Flower, L-Theanine, Mucuna Pruriens, Ashwagandha, Holy Basil, Magnolia Bark, Wild JujubeNatural Mixed Berry Lemon flavorMushroom Adaptogen
More news about: Barker Wellness
Apr 29, 2026, 16:15 ET VIAVI Announces Third Quarter Fiscal 2026 Results
Spirent Communications plc; (k) challenges integrating the businesses the Company has acquired and realizing all of the expected benefits and savings; (l) supply chain and materials constraints and the ability of our suppliers and contract manufacturers to meet production and delivery requirements to our
More news about: VIAVI Financials
Apr 29, 2026, 16:05 ET BAUSCH HEALTH ANNOUNCES FIRST QUARTER 2026 RESULTS
Health (excluding B+L) (non-GAAP) to be meaningful information and utilizes it in decision making and for compensation purposes. Adjusted EBITDA for Bausch Health Excluding B+L (non-GAAP) is not intended to be representative of GAAP continuing operations and Adjusted EBITDA for B+L is not intended to
More news about: Bausch Health Companies Inc.
Apr 29, 2026, 16:01 ET Red Rock Resorts Announces First Quarter 2026 Results
http://redrockresorts.investorroom.com/:Investors:Stephen L. [email protected](702)
More news about: Red Rock Resorts, Inc.
Apr 29, 2026, 15:45 ET Greenberg Traurig Adds Prominent Litigators Michael Collyard and Peter Ihrig in Minneapolis
Brian L. Duffy, chief executive officer of Greenberg Traurig. "Their depth of experience in financial fraud, receivership and trustee matters,
More news about: Greenberg Traurig, LLP
Apr 29, 2026, 14:08 ET University of Bridgeport Announces Full Keynote and Student Commencement Speaker Lineup
voices of the graduating classes through two student speakers whose experiences reflect the depth and diversity of the UB student community.Ananda L. Lindsey, of Easton, Pennsylvania, will represent the undergraduate class of 2026. Lindsey will graduate with a Bachelor of Science in Health Sciences
More news about: University of Bridgeport
Apr 29, 2026, 13:41 ET Norgine anuncia la autorización de comercialización de la Comisión Europea para XOLREMDI® (mavorixafor)
https://rarediseases.org/rare-diseases/whim-syndrome/. Consultado en abril de 20263. Badolato R, Alsina L, Azar A, et al. A phase 3 randomized trial of mavorixafor, a CXCR4 antagonist, for WHIM syndrome. Blood. 2024;144(1):35-454. XOLREMDI
More news about: Norgine B.V.